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S U M M A R Y
Objective: Since 2006, human papillomavirus (HPV) vaccination has been routinely recommended for
adolescent females in the USA. The quadrivalent vaccine induces long-term seropositivity to HPV 6/11/
16, which may be useful as a marker for HPV vaccine coverage.
Methods: We evaluated vaccine type seropositivity (i.e., seropositivity to HPV 6/11/16 with or without
HPV18) among females aged 14–59 years participating in the 2003–2010 National Health and Nutrition
Examination Survey (cross-sectional, nationally representative surveys). We compared pre-vaccine era
(2003–2006) to vaccine era (2007–2010) seropositivity and assessed agreement between vaccine era
seropositivity and reported vaccination by kappa statistic.
Results: Seropositivity was 1.0% among 2151 females in the pre-vaccine era and 22.1% among
1420 females in the vaccine era (p < 0.001); 23.1% of vaccine era females reported receipt of one or more
HPV vaccine dose. Seropositivity and reported vaccination had high agreement (kappa = 0.79; 95%
conﬁdence interval 0.74–0.84). Among seropositive females, 14.5% reported no vaccination.
Conclusion: The increase in vaccine era seropositivity likely reﬂects vaccination uptake. Our study
suggests seropositivity to HPV 6/11/16 may be a useful marker for vaccination coverage in adolescent
and young adult females. Discordance between seropositivity and reported vaccination may be
explained by inaccurate reporting and/or natural exposure to HPV.
Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Since 2006, the Advisory Committee on Immunization Practices
(ACIP) has recommended routine vaccination of females in the USA
aged 11 or 12 years, and for those aged 13–26 years not previously
vaccinated, with three doses of quadrivalent human papillomavi-
rus (HPV) vaccine;1 this recommendation was updated in 2009 to
include either quadrivalent or bivalent vaccine.2 Since 2011, ACIP
has recommended routine vaccination of males with quadrivalent§ Disclaimer: The ﬁndings and conclusions in this report are those of the authors
and do not necessarily represent the ofﬁcial position of the United States Centers for
Disease Control and Prevention (CDC). Mention of company names or products does
not imply endorsement by CDC.
* Corresponding author. Tel.: +1 404 639 1817; fax: +1 404 639 8606.
E-mail address: xfq7@cdc.gov (E.Y. Petrosky).
http://dx.doi.org/10.1016/j.ijid.2015.01.010
1201-9712/Published by Elsevier Ltd on behalf of International Society for Infectious
creativecommons.org/licenses/by-nc-nd/4.0/).vaccine.3 Both vaccines have demonstrated >93% efﬁcacy in
preventing cervical precancers associated with HPV 16 and 18,4,5
which cause 70% of cervical cancers.6 The quadrivalent vaccine also
prevents HPV 6 and 11, which cause 90% of genital warts.7 In the
USA, almost all HPV vaccine used is the quadrivalent vaccine.8 HPV
vaccine uptake remains low compared to other adolescent
vaccines;9 in 2013, only 37.6% of females aged 13–17 years had
received all three doses of the HPV vaccine.10
Accurate estimates of HPV vaccination coverage are needed
to monitor vaccination programs, identify under-vaccinated
populations, and inform efforts to improve coverage. Adolescent
vaccination coverage in the USA is measured by annual national
surveys involving veriﬁcation with provider vaccination records.9
Data from provider-veriﬁed vaccination are considered the most
accurate sources of information, but collection may not be feasible
in many settings.11 Other sources of information include Diseases. This is an open access article under the CC BY-NC-ND license (http://
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report of vaccination relies on memory and/or household-retained
vaccination cards and may be subject to recall bias.12,13 Vaccine
registries are often incomplete or non-existent for adolescent
immunizations.14 An alternative method for estimating vaccine
coverage may be serological assessment of antibodies to HPV
vaccine types.
The serological response to HPV infection differs from the
serological response to vaccination. Natural infection does not
always result in seroconversion.15 In one study, only 69% of
females seroconverted after infection with HPV6, and seroconver-
sion rates were lower for HPV 16 and 18.16 Prior to implementation
of the HPV vaccination program, seropositivity to at least three of
the four HPV vaccine types was only 2.8% among females aged 14–
59 years in the USA.17 In contrast, quadrivalent HPV vaccination
has been shown to induce seroconversion to all four vaccine types
(HPV 6/11/16/18) with geometric mean antibody titers much
higher than natural infection.18 However, up to 40% of participants
in clinical trials had undetectable antibody to HPV18 at 4 years
after vaccination by one serological assay,19,20 although there was
continued efﬁcacy against disease outcomes. Given this serological
response to HPV vaccination, we focused our assessment on what
is likely to be a sensitive and speciﬁc serological marker of
vaccination, seropositivity to HPV 6, 11, and 16 (with or without
seropositivity to HPV 18), referred to as HPV 6/11/16. This marker
would detect vaccinated persons who may have lost detectable
antibody to HPV18.
To evaluate the use of serology as a marker for vaccination
coverage, we describe HPV vaccine type seropositivity in the pre-
vaccine and vaccine eras and compare seropositivity to HPV 6/11/
16 with report of HPV vaccination in females using data from
the National Health and Nutrition Examination Survey (NHANES).
We restricted our assessment to females because few males were
vaccinated during the NHANES cycles we analyzed.
2. Methods
2.1. Survey design and study population
NHANES is an ongoing series of cross-sectional surveys
conducted by the National Center for Health Statistics (NCHS) of
the Centers for Disease Control and Prevention (CDC). The survey
is nationally representative of the civilian, non-institutionalized
US population. NHANES oversamples certain subpopulations to
increase the precision of estimates.21 Participants have a
household interview followed by a physical examination in a
mobile examination center (MEC). Written informed consent was
obtained from all participants and parental permission for
participants aged <18 years. This survey was approved by the
NCHS/CDC Research Ethics Review Board.
We analyzed NHANES 2003–2010 data and considered years
2003–2006 the pre-vaccine era and years 2007–2010 the vaccine
era. All female subjects aged 14–59 years selected for NHANES
2003–2010 were eligible for serological testing. In the pre-vaccine
era, 5178 females aged 14–59 years were interviewed; 4990
(96.4%) received a physical examination and 4531 (87.5%) serum
samples were collected and analyzed. In the vaccine era,
4988 females aged 14–59 years were interviewed; 4860 (97.8%)
received a physical examination and 4457 (89.7%) serum samples
were collected and analyzed.
2.2. Sociodemographic, behavioral, and HPV vaccination information
Sociodemographic information was ascertained during the
household interview. Race/ethnicity categories in NHANES
2003–2010 were self-reported and included non-Hispanic Black,non-Hispanic White, and Mexican American. Health insurance
categories included public/government, private, or no insurance.
Report of HPV vaccination was collected from 2007 to 2010. Parti-
cipants aged 16 years and emancipated minors were interviewed
directly; for those aged <16 years, parents or guardians were
interviewed. The question to assess vaccination was ‘‘Human
papillomavirus (HPV) vaccine is given to prevent cervical cancer in
girls and women. It is given in 3 separate doses over 6 months and
has been recommended for girls and women since June 2006.
{Have you/has participant} ever received one or more doses of the
HPV vaccine?’’ Answers included ‘‘Yes’’, ‘‘No’’, and ‘‘Don’t know’’.
Participants who responded ‘‘Yes’’ were asked ‘‘How many doses
{have you/has participant} received?’’ Answers included ‘‘1 dose’’,
‘‘2 doses’’, ‘‘3 doses’’, or ‘‘Don’t know’’.
2.3. Serological testing
Serum samples from NHANES participants were heat-inacti-
vated and blindly tested in duplicate using a multiplexed,
competitive Luminex immunoassay (cLIA) performed by Merck
Research Laboratories (Wayne, PA, USA) or Pharmaceutical
Product Development Inc. (Wayne, PA, USA). This assay was used
in the quadrivalent vaccine trials and measures antibodies to a
type-speciﬁc neutralizing epitope on virus-like particle 6/11/16/
18, as described elsewhere.22 Antibody levels for each HPV type
were reported as positive or negative on the basis of serostatus
cutoff values expressed as arbitrary units, established by Merck
(i.e., milli-Merck units per milliliter).22 Seropositivity for individ-
ual HPV types was deﬁned as anti-HPV antibody titers 20 mMU/
ml for HPV6, 16 mMU/ml for HPV11, 20 mMU/ml for HPV16,
and 24 mMU/ml for HPV18.22
2.4. Statistical analysis
Statistical analyses were conducted using SAS 9.3 (SAS, Inc.,
Cary, NC, USA) and SAS-callable SUDAAN 11.0 (Research Triangle
Institute, Research Triangle Park, NC, USA) to calculate standard
errors that account for the complex survey design. Estimates were
weighted using the MEC weights provided by NCHS for survey
years 2003–2010 to be nationally representative and to account for
non-response to the interview and medical examination and
oversampling of certain populations.21
We report seropositivity to HPV vaccine types in the pre-
vaccine era (2003–2006) and vaccine era (2007–2010) in females
aged 14–59 years by age group. In the vaccine era, we determined
receipt of at least one HPV vaccine dose (i.e., vaccine initiation) in
females aged 14–59 years and examined factors associated with
seropositivity to HPV vaccine types in females aged 14–26 years,
the age group in NHANES eligible for HPV vaccination. We
measured the agreement between report of vaccination and
seropositivity to HPV 6/11/16 using the kappa statistic.23 We
evaluated seropositivity in the vaccine era by selected demo-
graphic characteristics and examined bivariate statistical associa-
tions using the adjusted Wald F-test. Estimates were considered
unreliable if the relative standard error (RSE) was >30%. Two-sided
p-values <0.05 were considered signiﬁcant.
3. Results
3.1. Seropositivity in the pre-vaccine era (2003–2006) and vaccine
era (2007–2010) and report of HPV vaccination in the vaccine era
(2007–2010) in females aged 14–59 years
Seropositivity to HPV 6/11/16 in the pre-vaccine and vaccine
eras by age group is shown in Figure 1. Seropositivity to HPV 6/11/
16 increased signiﬁcantly from the pre-vaccine to vaccine eras in
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Figure 1. Seropositivity to HPV 6/11/16a by age group in the pre-vaccine era (2003–2006) and vaccine era (2007–2010) and reported receipt of one or more dose of HPV
vaccine in the vaccine era in females aged 14–59 yearsb; National Health and Nutrition Examination Survey, 2003–2010.
HPV, human papillomavirus.
aWith or without seropositivity to HPV18.
bAt the time of the survey.
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0.2–1.3) to 32.5% (95% CI 27.5–38.0) in females aged 14–19 years,
from 1.0% (95% CI 0.5–2.1) to 16.2% (95% CI 11.8–21.7) in females
aged 20–24 years, and from 2.3% (95% CI 1.2–4.4) to 6.9% (95%
CI 4.7–9.9) in females aged 25–29 years. In the older age groups
(>30 years of age), there were no statistically signiﬁcant
differences between the two eras.
A total of 4782 females aged 14–59 years responded to the HPV
vaccination question. Vaccine initiation varied signiﬁcantly by age
group (p < 0.001) and was reported by 32.9% (95% CI 27.9–38.2%)
of females aged 14–19 years, 17.7% (95% CI 12.5–24.4%) of females
aged 20–24 years, and 7.6% (95% CI 5.4–10.7%) of females agedTable 1
Seropositivity to HPV 6, 11, 16, and 18 in the vaccine era in females aged 14–26 years
Group No. subjects 
HPV6 HPV11 HPV16 
Overallc 1420 34.9 (31.0–38.9) 25.6 (22.1–29.4) 32.9 (29.4
Age, years
** 
14–19 779 36.2 (31.6–41.1) 35.2 (30.4–40.2) 35.6 (31.5
20–26 641 33.8 (29.2–38.7) 17.6 (13.6–22.5) 30.0 (25.5
Race/ethnicity
** ** 
White, non-Hispanic 499 36.4 (30.5–42.8) 28.6 (23.2–34.6) 36.1 (30.7
Black, non-Hispanic 301 40.4 (35.5–45.6) 21.7 (17.8–26.1) 34.4 (30.3
Mexican American 353 27.2 (21.8–33.3) 19.8 (14.4–26.6) 23.0 (17.6
Report of vaccinationd
** ** ** 
1 HPV vaccine 324 84.9 (81.0–88.1) 88.3 (85.3–90.8) 89.9 (86.7
No HPV vaccine 1067 20.2 (17.0–23.7) 6.9 (5.2–9.2) 16.1 (13.3
HPV, human papillomavirus; CI, conﬁdence interval.
a Age at the time of the survey.
b With or without seropositivity to HPV18.
c Includes females aged 14–26 years with valid HPV serology results.
d Includes females aged 14–26 years with valid HPV serology results and who respo
*
P <0.05.
**
P <0.01.25–29 years (Figure 1). In the older age groups, report of vaccine
initiation ranged from 0.8% to 3.1%.
3.2. HPV seropositivity in the vaccine era (2007–2010) in females
aged 14–26 years
A total of 1420 females aged 14–26 years had valid serology
results (Table 1). Overall, 44.1% were seropositive for any HPV
vaccine type and 17.1% were seropositive for all four HPV vaccine
types. Seropositivity to individual HPV types 6, 11, 16, and 18 were
34.9%, 25.6%, 32.9%, and 21.1%, respectively. Seropositivity to HPV
6/11/16 was 22.1%. Seropositivity to any HPV vaccine type wasa; National Health and Nutrition Examination Survey, 2007–2010.
Weighted % (95% CI)
HPV18 Any HPV HPV 6/11/16b All 4 HPV types
–36.8) 21.1 (17.9–24.7) 44.1 (40.2–48.1) 22.1 (18.7–25.9) 17.1 (14.0–20.6)
** * ** **
–42.0) 26.6 (21.8–32.0) 40.1 (35.4–44.9) 32.5 (27.5–38.0) 25.9 (21.2–31.3)
–34.8) 16.6 (12.9–21.1) 47.4 (42.4–52.5) 13.5 (9.8–18.2) 9.7 (6.5–14.3)
** ** *
–41.8) 22.9 (18.5–27.9) 45.3 (39.6–51.0) 25.5 (20.3–31.5) 19.8 (15.5–24.9)
–38.7) 24.2 (19.5–29.6) 56.0 (50.3–61.6) 16.1 (12.7–20.2) 12.4 (8.3–18.0)
–29.4) 12.2 (8.2–17.7) 33.7 (26.9–41.2) 16.0 (11.2–22.4) 10.9 (7.2–16.1)
** ** ** **
–92.5) 65.8 (59.3–71.8) 92.3 (88.7–94.9) 82.5 (78.7–85.8) 64.0 (57.4–70.0)
–19.3) 7.9 (6.2–10.0) 30.0 (26.2–34.1) 4.2 (2.7–6.52) 3.1 (1.9–4.9)
nded to the HPV vaccination question with ‘‘Yes’’ or ‘‘No’’.
Table 2
Report of no HPV vaccination among those seropositive for HPV 6/11/16a in females
aged 14–26 yearsb, by selected characteristics; National Health and Nutrition
Examination Survey, 2007–2010
Characteristics No. subjects Seropositive for HPV 6/11/16a
Weighted % reporting
no vaccination (95%
CI)
p-value
Overall 309 14.5 (9.3–21.9)
Age, years 0.58
14–19 235 13.4 (8.6–20.4)
20–26 74 16.7c (7.9–31.9)
Race/ethnicity 0.09
White, non-Hispanic 134 12.7c (6.2–24.2)
Black, non-Hispanic 54 33.4 (18.5–52.5)
Mexican American 65 13.7 (7.4–24.2)
Health insurance 0.38
Public/government 107 15.5 (9.6–23.9)
Private 157 12.9c (6.6–24.0)
None 41 23.4 (12.3–39.8)
HPV, human papillomavirus; CI, conﬁdence interval.
a With or without seropositivity to HPV18.
b Includes females aged 14–26 years at the time of the survey, seen in the mobile
examination center (MEC) with valid HPV serology who were seropositive for HPV
6/11/16 (with or without seropositivity to HPV18).
c Relative standard error (RSE) >30%.
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19 years (47.4% vs. 40.1%; p < 0.05). In contrast, seropositivity to all
four HPV vaccine types was higher in the younger age group
compared to the older age group (25.9% vs. 9.7%; p < 0.01), as was
seropositivity to HPV 6/11/16 (32.5% vs. 13.5%; p < 0.01).
When examined by race/ethnicity, seropositivity to any HPV
vaccine type was highest in non-Hispanic Blacks (56.0%), followed
by non-Hispanic Whites (45.3%) and Mexican Americans (33.7%)
(p < 0.01), whereas seropositivity to all four HPV vaccine types was
highest in non-Hispanic Whites (19.8%), followed by non-Hispanic
Blacks (12.4%) and Mexican Americans (10.9%) (p < 0.05). There
was no statistically signiﬁcant difference by race/ethnicity for
seropositivity to HPV 6/11/16.
Of 1391 females with valid serology results and vaccination
data, 23.1% reported vaccine initiation. Of 1382 females who
reported the number of doses received, 6.3% reported receipt of
only one dose, 5.4% only two doses, 14.6% all three vaccine doses;
the remaining 73.7% reported no HPV vaccination. In those who
reported vaccine initiation, 92.3% were seropositive for any HPV
vaccine type; 84.9%, 88.3%, 89.9%, and 65.8% were seropositive for
HPV 6, 11, 16, and 18, respectively. In those reporting no HPV
vaccination, seropositivity to any HPV vaccine type was 30.0% and
seropositivity to individual HPV types ranged from 6.9% to 20.2%.
Seropositivity to HPV 6/11/16 types was 82.5% for those reporting
vaccine initiation and 4.2% for those reporting no vaccination.
Seropositivity to all four HPV vaccine types was 64.0% for those
reporting vaccine initiation and 3.1% for those reporting no
vaccination.
3.3. Seropositivity to HPV 6/11/16 and report of HPV vaccination in
the vaccine era (2007–2010) in females aged 14–26 years
There were 309 females seropositive for HPV 6/11/16; of these,
85.5% reported HPV vaccine initiation. Of the 1082 females who
were not seropositive for HPV 6/11/16, 94.8% reported no HPV
vaccination and 5.2% reported HPV vaccine initiation. The overall
kappa for seropositivity to HPV 6/11/16 and HPV vaccine initiation
was 0.79 (95% CI 0.74–0.84). The kappa for seropositivity to HPV 6/
11/16 and vaccination increased with increasing number of doses;
from 0.49 (95% CI 0.34–0.63) for report of one dose to 0.62 (95% CI
0.59–0.74) for report of two doses and 0.84 (95% CI 0.78–0.89) for
report of three doses.
We further examined those with discrepant ﬁndings between
seropositivity and report of vaccination. Among females seroposi-
tive for HPV 6/11/16, 14.5% reported no HPV vaccination (Table 2);
there were no signiﬁcant differences in the percentage of females
reporting no vaccination by age, race/ethnicity, or health insur-
ance.
4. Discussion
In this nationally representative survey, we found seropositivi-
ty to HPV 6/11/16 was signiﬁcantly higher in the vaccine era
(2007–2010) compared to the pre-vaccine era (2003–2006) in
adolescent and young adult females. We also found high
agreement between seropositivity to HPV 6/11/16 and report of
HPV vaccination. Our study suggests seropositivity to HPV 6/11/16
(with or without seropositivity to HPV 18) may be a useful marker
for quadrivalent HPV vaccination coverage.
HPV vaccination results in high seroconversion for all vaccine
types with higher antibody titers than natural infection.18 This
differs from some other vaccines, which produce antibody titers
lower than natural infection.24–26 Efﬁcacy has been very high in all
vaccine trials to date and a serological correlate of immunity has
not been established.27 Previous studies of HPV-vaccinated
individuals suggest seropositivity to HPV18, when measured bythe cLIA, may decline over time,19,20 although antibodies were
detected by other assays.28 Consistent with those studies, we
found seropositivity to HPV18 in females reporting vaccination to
be lower than other vaccine types using the cLIA (65.8% vs. 84.9–
89.9%).
The high agreement between seropositivity to HPV 6/11/16 and
report of vaccination in females aged 14–26 years increased with
increasing vaccine dose, which may indicate incomplete serologi-
cal detection of HPV vaccination or more accurate reporting of
vaccination with receipt of an increasing number of vaccine doses.
Parent-reported vaccination has been shown to have high
agreement with provider-veriﬁed vaccination records for receipt
of at least one HPV vaccine dose (kappa = 0.76) and all three doses
(kappa = 0.74) in females aged 13–17 years,29 but this might vary
over time and in different demographic groups. Although we were
unable to validate report of HPV vaccination with provider
veriﬁcation, our results are similar to vaccination coverage
estimates from national immunization surveys.30
Although we found high agreement between seropositivity to
HPV 6/11/16 and report of vaccination, some females aged 14–26
years were seropositive for HPV 6/11/16 and reported no
vaccination. It is unclear if this is due to under-reporting of
vaccination, naturally acquired HPV 6/11/16 infection,17 or both. In
one study comparing parent-report of HPV vaccination with
provider record veriﬁcation for females aged 13–17 years, certain
demographic groups had a higher probability of false-negative
parental report.31 Also, age may confound analyses, as older age is
associated with a higher likelihood of exposure to HPV. Future
assessments should compare seropositivity to HPV 6/11/16 with
provider report of vaccination to evaluate discrepant ﬁndings.
This study is subject to several limitations. First, misclassiﬁca-
tion of HPV vaccination could have occurred with report of
vaccination and seropositivity to at least three HPV vaccine types;
either measure could have over- or under-estimated actual HPV
vaccination. However, for report of vaccination, the short duration
between licensure of the HPV vaccine and the NHANES cycles we
analyzed would minimize recall bias. Second, the small sample size
in some groups limited our ability to conduct stratiﬁed sub-
analyses; we were unable to further examine females who were
not seropositive for HPV 6/11/16 but reported HPV vaccination.
E.Y. Petrosky et al. / International Journal of Infectious Diseases 33 (2015) 137–141 141Third, our ﬁndings are speciﬁc for the quadrivalent HPV vaccine,
seropositivity as measured by the cLIA, and females in the USA.
Future assessments should evaluate serological markers in global
settings with different serological assays and for bivalent vaccine
and second-generation vaccines that target additional HPV vaccine
types.32
Population-based serological studies for vaccine type HPV
provide a biological marker not subject to reporting bias and may
be useful in settings where assessment of vaccination through
provider or patient report is not feasible. However, while
serological studies may provide information on vaccine uptake,
such evaluations cannot determine number of doses or age at
vaccination.
In conclusion, this is the ﬁrst study to compare report of HPV
vaccination and HPV seropositivity. Seropositivity to HPV 6/11/16
increased in adolescent and young adult females in the vaccine era.
Our ﬁndings suggest seropositivity to HPV 6/11/16 (with or
without seropositivity to HPV18) may be used to assess
quadrivalent HPV vaccine initiation in the general population,
especially in the young age groups targeted by the HPV vaccine.
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